News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
18,207 Results
Type
Article (773)
Company Profile (3)
Press Release (17431)
Section
Business (4979)
Career Advice (2)
Deals (1048)
Drug Delivery (1)
Drug Development (2057)
Employer Resources (1)
FDA (335)
Job Trends (302)
News (8422)
Policy (711)
Tag
2024 Genetown Standard (1)
Academia (23)
Alliances (1530)
ALS (3)
Alzheimer's disease (7)
Approvals (340)
Artificial intelligence (9)
Autoimmune disease (1)
Automation (1)
Bankruptcy (7)
Best Places to Work (250)
Biosimilars (1)
Biotechnology (5)
Bladder cancer (3)
Brain cancer (1)
Breast cancer (2)
Cancer (57)
Cardiovascular disease (7)
Career advice (2)
CAR-T (1)
Cell therapy (5)
Clinical research (1666)
Collaboration (20)
Compensation (7)
Complete response letters (1)
COVID-19 (142)
C-suite (11)
Data (65)
Depression (1)
Diabetes (9)
Diagnostics (301)
Drug discovery (2)
Drug pricing (1)
Earnings (2058)
Editorial (1)
Employer resources (1)
Events (2797)
Executive appointments (19)
FDA (360)
Funding (11)
Gene editing (1)
Generative AI (2)
Gene therapy (4)
GLP-1 (58)
Government (64)
Healthcare (583)
Immunology and inflammation (1)
Indications (2)
Infectious disease (146)
Inflammatory bowel disease (3)
Inflation Reduction Act (1)
Influenza (6)
Intellectual property (2)
IPO (446)
IRA (2)
Job creations (68)
Job search strategy (2)
Layoffs (5)
Legal (177)
Liver cancer (1)
Lung cancer (18)
Lymphoma (6)
Manufacturing (2)
MASH (2)
Medical device (531)
Medtech (531)
Mergers & acquisitions (618)
Metabolic disorders (16)
Multiple sclerosis (1)
Neurodegenerative disease (2)
Neuroscience (16)
NextGen: Class of 2025 (88)
Non-profit (20)
Northern California (41)
Obesity (8)
Opinion (1)
Ovarian cancer (1)
Pain (2)
Pancreatic cancer (3)
Parkinson's disease (3)
Patents (1)
Patient recruitment (1)
People (1243)
Phase I (542)
Phase II (778)
Phase III (575)
Pipeline (32)
Policy (2)
Postmarket research (64)
Preclinical (226)
Press Release (1)
Radiopharmaceuticals (5)
Real estate (112)
Recruiting (1)
Regulatory (525)
Reports (3)
Research institute (26)
RSV (1)
Series A (2)
Series B (3)
Southern California (25)
Startups (89)
Supply chain (1)
United States (381)
Vaccines (28)
Venture capitalists (2)
Weight loss (3)
Date
Today (6)
Last 7 days (24)
Last 30 days (73)
Last 365 days (1015)
2025 (145)
2024 (1014)
2023 (1043)
2022 (2128)
2021 (1786)
2020 (1268)
2019 (917)
2018 (795)
2017 (1022)
2016 (1052)
2015 (1199)
2014 (813)
2013 (548)
2012 (698)
2011 (624)
2010 (587)
Location
Africa (9)
Alabama (1)
Arizona (4)
Asia (526)
Australia (158)
California (83)
Canada (29)
Connecticut (25)
Europe (6733)
Florida (22)
Georgia (2)
Illinois (3)
Indiana (2)
Japan (1)
Maryland (29)
Massachusetts (118)
Michigan (2)
Minnesota (1)
Nebraska (1)
Nevada (17)
New Jersey (47)
New York (6)
North Carolina (7)
Northern California (41)
Pennsylvania (9)
Rhode Island (1)
South America (12)
South Carolina (1)
Southern California (25)
Texas (15)
Utah (2)
Virginia (2)
Washington State (1)
18,207 Results for "complix nv".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Update with KOL Speakers
February 19, 2025
·
8 min read
Press Releases
Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements
January 27, 2025
·
3 min read
Press Releases
Vivoryon Therapeutics N.V. to Host Virtual R&D Update with KOL Speakers on February 18, 2025
February 11, 2025
·
4 min read
Press Releases
QIAGEN N.V. to Release Results for Q4 2024 and Hold Webcast
January 15, 2025
·
1 min read
Press Releases
Vivoryon Therapeutics N.V. Provides R&D-Update Further Strengthening Development Pipeline in Kidney Disease
January 14, 2025
·
10 min read
Press Releases
Press Release Biocartis NV: Biocartis announces new data on early CAR-T vector load assessment with Idylla™ presented at ASTCT: A Potential Breakthrough in LBCL Treatment Monitoring
February 14, 2025
·
3 min read
QIAGEN N.V. to release results for Q1 2024 and hold webcast
QIAGEN N.V. announced plans to release results for the first quarter 2024.
April 9, 2024
·
1 min read
Press Releases
NanoViricides, Inc. Has Filed Its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID
November 15, 2024
·
11 min read
Pharm Country
Orally Administered NV-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effect
NanoViricides, Inc. reports that its clinical stage lead nanoviricide broad-spectrum antiviral drug candidate, NV-387, results in an ideal flat blood concentration profile for an extended time period upon oral administration in two different animal models.
June 11, 2024
·
9 min read
Pharm Country
Lethally RSV Infected Animals Orally Treated with NV-387 Showed Normal Lung Histology, Indicating Potential Cure
NanoViricides, Inc., a global leader in broad-spectrum antiviral nanomedicines, says that the strong antiviral activity of NV-387 against RSV/A2 is clearly demonstrated by lungs remaining normal and showing no infection-related damage, when treated orally with NV-387, in a lethal lung RSV infection animal model.
May 20, 2024
·
7 min read
1 of 1,821
Next
